223 related articles for article (PubMed ID: 26861605)
21. Improved survival in metastatic germ-cell cancer.
Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
[TBL] [Abstract][Full Text] [Related]
22. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
J Clin Oncol; 1997 Feb; 15(2):594-603. PubMed ID: 9053482
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
[TBL] [Abstract][Full Text] [Related]
24. Outcome of patients with stage II and III nonseminomatous germ cell tumors: results of a single center.
Ataergin S; Ozet A; Arpaci F; Kilic S; Beyzadeoglu M; Komurcu S
Indian J Cancer; 2007; 44(1):6-11. PubMed ID: 17401218
[TBL] [Abstract][Full Text] [Related]
25. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
26. Neutrophil-to-lymphocyte ratio in primary mediastinal germ cell tumors: A retrospective analysis of >20 years single institution experience.
Géczi L; Budai B; Polk N; Fazekas F; Bodrogi I; Biró K
Curr Probl Cancer; 2020 Aug; 44(4):100537. PubMed ID: 31980147
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
[TBL] [Abstract][Full Text] [Related]
28. Primary mediastinal germ cell tumors - A retrospective analysis of >30 years of experience in a single institution.
Koizumi T; Kanda S; Nihonmatu R; Gomi D; Sekiguchi N; Noguchi T; Fukushima T; Kobayashi T; Yamamoto H; Takeda T
Thorac Cancer; 2021 Mar; 12(6):807-813. PubMed ID: 33502089
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
[TBL] [Abstract][Full Text] [Related]
30. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
[TBL] [Abstract][Full Text] [Related]
31. Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors.
Ganjoo KN; Rieger KM; Kesler KA; Sharma M; Heilman DK; Einhorn LH
Cancer; 2000 Mar; 88(5):1051-6. PubMed ID: 10699894
[TBL] [Abstract][Full Text] [Related]
32. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.
Feldman DR; Lorch A; Kramar A; Albany C; Einhorn LH; Giannatempo P; Necchi A; Flechon A; Boyle H; Chung P; Huddart RA; Bokemeyer C; Tryakin A; Sava T; Winquist EW; De Giorgi U; Aparicio J; Sweeney CJ; Cohn Cedermark G; Beyer J; Powles T
J Clin Oncol; 2016 Feb; 34(4):345-51. PubMed ID: 26460295
[TBL] [Abstract][Full Text] [Related]
33. Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer.
Schneider BP; Kesler KA; Brooks JA; Yiannoutsos C; Einhorn LH
J Clin Oncol; 2004 Apr; 22(7):1195-200. PubMed ID: 15051766
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
35. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors.
Hartmann JT; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Kanz L; Einhorn L; Bokemeyer C
Ann Oncol; 2002 Jul; 13(7):1017-28. PubMed ID: 12176779
[TBL] [Abstract][Full Text] [Related]
36. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.
Fizazi K; Tjulandin S; Salvioni R; Germà-Lluch JR; Bouzy J; Ragan D; Bokemeyer C; Gerl A; Fléchon A; de Bono JS; Stenning S; Horwich A; Pont J; Albers P; De Giorgi U; Bower M; Bulanov A; Pizzocaro G; Aparicio J; Nichols CR; Théodore C; Hartmann JT; Schmoll HJ; Kaye SB; Culine S; Droz JP; Mahé C
J Clin Oncol; 2001 May; 19(10):2647-57. PubMed ID: 11352956
[TBL] [Abstract][Full Text] [Related]
37. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
40. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]